{"brief_title": "Phase III Multicenter, Open-Label, Randomized Trial of Induction Versus Induction Plus Maintenance Foscarnet ( Foscavir ) Therapy for Gastrointestinal CMV Disease", "brief_summary": "PRIMARY: To compare the frequency of and time to relapse of Cytomegalovirus (CMV) gastrointestinal disease following foscarnet induction therapy only versus induction plus maintenance therapy. SECONDARY: To determine frequency of and time to recurrence of gastrointestinal symptoms, response rate of pathological lesions, and incidence of nongastrointestinal CMV disease in this patient population.", "detailed_description": "Patients receive intravenous foscarnet either as induction only for 4 weeks or as induction for 4 weeks followed by maintenance for 22 weeks. All patients are followed for 26 weeks or until relapse.", "condition": "Gastrointestinal Diseases", "intervention_type": "Drug", "intervention_name": "Foscarnet sodium", "criteria": "Inclusion Criteria Patients must have: - AIDS. - CMV GI disease. Exclusion Criteria Co-existing Condition: Patients with the following symptoms or conditions are excluded: - Non-GI CMV disease. - Ulcerative colitis, inflammatory bowel disease, or other condition that may interfere with study results. - Other GI pathogens. Concurrent Medication: Excluded: - Drugs that may interact with foscarnet. - Systemic acyclovir, ganciclovir, or acyclovir prodrug. - Drugs known to affect renal function. Prior Medication: Excluded: - Prior foscarnet in extremis. - Investigational agents other than 3TC or d4T within 7 days prior to study entry.", "gender": "All", "minimum_age": "18 Years", "maximum_age": "N/A", "healthy_volunteers": "No", "id": "NCT00002145.xml"}